{"entity":{"id":"nct04481763","kind":"trial","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","aka":[],"tldr":"A phase 1/2 trial of camrelizumab in triple-negative breast cancer, run by Jiangxi Provincial Cancer Hospital, now recruiting.","summary":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast is a phase 1/2, interventional study registered as NCT04481763 by Jiangxi Provincial Cancer Hospital, with a registry enrolment figure of 20 participants, started 2020-07-14 and due to reach its primary completion in 2024-08-30. Interventions recorded: Camrelizumab; radiotherapy. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Participants with a histological or cytological diagnosis of TNBC breast cancer , defined by ER \\<1%, PR \\<1% and HER2 negative on IHC and/or non-amplified by ISH by local lab testing\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04481763","url":"https://clinicaltrials.gov/study/NCT04481763"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04481763","phase":"1/2","setting":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","sponsor":"Jiangxi Provincial Cancer Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04481763/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}